Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Inhibikase Therapeutics Inc IKT

Healthcare Biotechnology
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease... see more

Recent & Breaking News (NDAQ:IKT)

Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity

PR Newswire November 15, 2021

Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation Alpha-Synuclein Summit

PR Newswire October 27, 2021

Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009

PR Newswire October 19, 2021

Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease

PR Newswire October 4, 2021

Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy

PR Newswire September 23, 2021

Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference

PR Newswire September 7, 2021

Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity

PR Newswire August 16, 2021

Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients

PR Newswire July 26, 2021

Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock

PR Newswire June 18, 2021

Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock

PR Newswire June 15, 2021

Inhibikase Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference & Others

PR Newswire May 25, 2021

Inhibikase Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity

PR Newswire May 17, 2021

Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum

PR Newswire April 21, 2021

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity

PR Newswire April 1, 2021

Inhibikase Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Virtual Conference

PR Newswire March 2, 2021

Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference

PR Newswire February 22, 2021

Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson's Disease and Related Disorders

Business Wire February 17, 2021

Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer

PR Newswire January 4, 2021

Inhibikase Therapeutics Announces Closing of Initial Public Offering

PR Newswire December 28, 2020

Inhibikase Therapeutics, Inc. Announces Pricing of its Initial Public Offering

PR Newswire December 22, 2020